Single-dose cefodizime as infection prophylaxis in abdominal surgery: a prospective multicenter study
Related Experiment Videos
F Thalhammer1, F Traunmüller, H J Böhming
1Universitätsklinik für Innere Medizin I, Klinische Abt. für Infektionen und Chemotherapie, Wien, Austria.
Abstract:
This prospective pilot study was performed to evaluate the efficacy, safety and tolerability of a single dose of cefodizime as infection prophylaxis in patients undergoing major abdominal surgery. One hundred forty-nine patients received 2g cefodizime, a third-generation cephalosporin, 30 min before abdominal surgery. The mean operation time was 116 +/- 66 min. Eighteen patients received metronidazole additionally. In 8/149 patients (5.4%) the final outcome was considered to be a treatment failure. 94.6% of the patients had no signs of infection. The long half-life of cefodizime allows a single-dose perioperative prophylaxis even in abdominal surgery lasting 3 to 4 h. Cefodizime can be regarded as a safe antibiotic prophylaxis with few side effects.
Insights
A single dose of cefodizime effectively prevented infections in major abdominal surgery patients, demonstrating its safety and tolerability. This antibiotic prophylaxis proved successful in over 94% of cases.
Area of Science:
- Infectious Diseases
- Surgical Oncology
- Pharmacology
Background:
- Postoperative infections pose significant risks in major abdominal surgery.
- Effective antibiotic prophylaxis is crucial for reducing surgical site infections.
- Third-generation cephalosporins are commonly used for infection prevention.
Purpose of the Study:
- To evaluate the efficacy, safety, and tolerability of a single dose of cefodizime for infection prophylaxis.
- To assess cefodizime's suitability for perioperative use in major abdominal surgery.
- To determine the treatment failure rate and incidence of infection in patients receiving cefodizime prophylaxis.
Main Methods:
- A prospective pilot study involving 149 patients undergoing major abdominal surgery.
- Administration of a single 2g dose of cefodizime 30 minutes prior to surgery.
- Recording of operation time, additional antibiotic use (metronidazole), and patient outcomes regarding infection.
Main Results:
- 94.6% of patients experienced no signs of infection, indicating high efficacy.
- A low treatment failure rate of 5.4% (8/149 patients) was observed.
- Cefodizime demonstrated a favorable safety profile with few reported side effects.
Conclusions:
- A single dose of cefodizime is effective and safe for infection prophylaxis in major abdominal surgery.
- The long half-life of cefodizime supports its use as a single-dose perioperative prophylactic agent.
- Cefodizime represents a viable option for antibiotic prophylaxis in complex surgical procedures.
